User Tools

Site Tools


Antiplatelet drug

see Antiplatelet drugs and neurosurgical procedures.

Drugs that interfere with platelet function can be classified into 3 categories:

Those that prevent cardiovascular disease (primary prevention), those that treat an acute disease, and those that treat a chronic disease (secondary prevention)

There are both oral (taken by mouth) and intravenous (given through a vein) drugs that inhibit platelet function and are used to treat patients with cardiac and cerebrovascular diseases.

see Dual antiplatelet therapy.


The class of antiplatelet drugs include:

Irreversible cyclooxygenase inhibitors


Triflusal (Disgren)

Adenosine diphosphate (ADP) receptor inhibitors

Clopidogrel (Plavix)

Prasugrel (Effient)

Ticagrelor (Brilinta)

Ticlopidine (Ticlid)

Phosphodiesterase inhibitors

Cilostazol (Pletal)

Protease-activated receptor-1 (PAR-1) antagonists

Vorapaxar (Zontivity)

Glycoprotein IIB/IIIA inhibitors (intravenous use only)

Abciximab (ReoPro)

Eptifibatide (Integrilin)

Tirofiban (Aggrastat)

Adenosine reuptake inhibitors

Dipyridamole (Persantine)

Thromboxane inhibitors

Thromboxane synthase inhibitors

Thromboxane receptor antagonists


Among ICU patients admitted with intracranial hemorrhage, preadmission oral antiplatelet use was not associated with increased in-hospital mortality or hospital costs. These findings have important prognostic implications for clinicians who care for patients with intracranial hemorrhage 1)

An anonymous survey of 11 multiple-choice questions about management of aSAH patients with antiplatelet use before the initial hemorrhage was distributed to the international panel of attendees of the European Association of Neurosurgical Societies (EANS) annual meeting in Venice, Italy at 1-5 October 2017.

A total of 258 (54%) completed surveys were returned. In about 80%, the departments of neurosurgery and neurology were responsible for acute management of aSAH patients, whereas in 15% the intensive care unit. Department guidelines were present in 32%. In 65%, the responders always stop the antiplatelet agent at admission and in 4.3% are thrombocytes always transfused. When a guideline is present, the neurospecialists consider thrombocyte transfusion more often (83% vs. 65% p=0.02).

The survey among mainly European neurosurgeons show that there is a significant variability in the management of aSAH patients who have been using antiplatelets before the initial hemorrhage. These findings emphasize the importance of the development of evidence-based guidelines for management of patients with aSAH and antiplatelet use before the initial hemorrhage 2).

Fernando SM, Mok G, Rochwerg B, English SW, Thavorn K, McCredie VA, Dowlatshahi D, Perry JJ, Wijdicks EFM, Reardon PM, Tanuseputro P, Kyeremanteng K. Preadmission Antiplatelet Use and Associated Outcomes and Costs Among ICU Patients With Intracranial Hemorrhage. J Intensive Care Med. 2019 Nov 19:885066619885347. doi: 10.1177/0885066619885347. [Epub ahead of print] PubMed PMID: 31741418.
Sebök M, Keller E, van Niftrik CHB, Regli L, Germans MR. Management of aneurysmal subarachnoid hemorrhage patients with antiplatelet use before the initial hemorrhage: an international survey. World Neurosurg. 2018 Aug 24. pii: S1878-8750(18)31877-1. doi: 10.1016/j.wneu.2018.08.094. [Epub ahead of print] PubMed PMID: 30149168.
antiplatelet_drug.txt · Last modified: 2020/01/29 16:24 by administrador